153 related articles for article (PubMed ID: 15557765)
1. Treatment with fluvastatin rapidly modulates, via different pathways, and in dependence on the baseline level, inflammation in hemodialysis patients.
Tsirpanlis G; Boufidou F; Manganas S; Chantzis K; Bleta A; Stamatelou K; Psimenou E; Nicolaou C
Blood Purif; 2004; 22(6):518-24. PubMed ID: 15557765
[TBL] [Abstract][Full Text] [Related]
2. Release of interleukin-6 and its soluble receptors by activated peripheral blood monocytes is elevated in hypocholesterolemic hemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Alevyzaki F; Zoga M; Kyritsis I; Ioannou D; Fatourou A; Nicolaou C
Am J Nephrol; 2005; 25(5):484-90. PubMed ID: 16127269
[TBL] [Abstract][Full Text] [Related]
3. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
4. Short-term effects of fluvastatin therapy on plasma interleukin-10 levels in patients with chronic heart failure.
Tekin A; Sezgin N; Katircibaşi MT; Tekin G; Cölkesen Y; Sezgin AT; Müderrisoğlu H
Coron Artery Dis; 2008 Nov; 19(7):513-9. PubMed ID: 18923248
[TBL] [Abstract][Full Text] [Related]
5. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits.
Mendoza S; Gamez R; Mas R; Goicochea E
Int J Tissue React; 2003; 25(3):81-9. PubMed ID: 14756189
[TBL] [Abstract][Full Text] [Related]
6. The effect of different doses of fluvastatin on inflammatory markers in the early phase of acute coronary syndrome.
Yang J; Li XP; Zhao SP; Li J; Li JD; Xie XM
Clin Chim Acta; 2006 Jun; 368(1-2):183-7. PubMed ID: 16472797
[TBL] [Abstract][Full Text] [Related]
7. Effect of intradialytic intravenous administration of omega-3 fatty acids on nutritional status and inflammatory response in hemodialysis patients: a pilot study.
Szklarek-Kubicka M; Fijałkowska-Morawska J; Zaremba-Drobnik D; Uciński A; Czekalski S; Nowicki M
J Ren Nutr; 2009 Nov; 19(6):487-93. PubMed ID: 19616450
[TBL] [Abstract][Full Text] [Related]
8. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
Li JJ; Li YS; Chu JM; Zhang CY; Wang Y; Huang Y; Chen J; Yuan JQ; Huang YL
Clin Chim Acta; 2006 Apr; 366(1-2):269-73. PubMed ID: 16343471
[TBL] [Abstract][Full Text] [Related]
9. Pro- and anti-inflammatory cytokines in chronic pediatric dialysis patients: effect of aspirin.
Goldstein SL; Leung JC; Silverstein DM
Clin J Am Soc Nephrol; 2006 Sep; 1(5):979-86. PubMed ID: 17699316
[TBL] [Abstract][Full Text] [Related]
10. Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma.
Urbańska-Ryś H; Wiersbowska A; Stepień H; Robak T
Eur Cytokine Netw; 2000 Sep; 11(3):443-51. PubMed ID: 11022130
[TBL] [Abstract][Full Text] [Related]
11. Effect of fluvastatin on serum prohepcidin levels in patients with end-stage renal disease.
Arabul M; Gullulu M; Yilmaz Y; Akdag I; Kahvecioglu S; Eren MA; Dilek K
Clin Biochem; 2008 Sep; 41(13):1055-8. PubMed ID: 18571502
[TBL] [Abstract][Full Text] [Related]
12. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
13. Main determinants of PON1 activity in hemodialysis patients.
Ribeiro S; do Sameiro Faria M; Mascarenhas-Melo F; Freitas I; Mendonça MI; Nascimento H; Rocha-Pereira P; Miranda V; Mendonça D; Quintanilha A; Belo L; Costa E; Reis F; Santos-Silva A
Am J Nephrol; 2012; 36(4):317-23. PubMed ID: 23007074
[TBL] [Abstract][Full Text] [Related]
14. A vitamin E-coated polysulfone membrane reduces serum levels of inflammatory markers and resistance to erythropoietin-stimulating agents in hemodialysis patients: results of a randomized cross-over multicenter trial.
Panichi V; Rosati A; Paoletti S; Ferrandello P; Migliori M; Beati S; Bernabini G; Daini R; Casani A; Angelini D; Parrini M; Rossi A; Petrone I; Barsotti G; Donadio C; Donati G; Grazi G; Manca Rizza G; Garosi G; Sansoni E; Braccagni B; Sidoti A; Boracelli D; Biagioli M; Moriconi L; Finato V; Mannarino A; Grimaldi C; Pansa F; Imperiali P; Mura C; Bianchi S; Bigazzi R
Blood Purif; 2011; 32(1):7-14. PubMed ID: 21242686
[TBL] [Abstract][Full Text] [Related]
15. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients.
Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Zoga M; Alevyzaki F; Stamatelou K; Frangou E; Savva L; Nicolaou C
Nephrology (Carlton); 2006 Dec; 11(6):506-9. PubMed ID: 17199788
[TBL] [Abstract][Full Text] [Related]
16. Does fluvastatin favour HCV replication in vivo? A pilot study on HIV-HCV coinfected patients.
Milazzo L; Meroni L; Galazzi M; Cesari M; Caramma I; Marchetti G; Galli M; Antinori S
J Viral Hepat; 2009 Jul; 16(7):479-84. PubMed ID: 19215577
[TBL] [Abstract][Full Text] [Related]
17. The effects of peritoneal dialysis and hemodialysis on serum tumor necrosis factor-alpha, interleukin-6, interleukin-10 and C-reactive-protein levels.
Borazan A; Ustün H; Ustundag Y; Aydemir S; Bayraktaroglu T; Sert M; Yilmaz A
Mediators Inflamm; 2004 Jun; 13(3):201-4. PubMed ID: 15223612
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin and fluvastatin reduce viremia and the pro-inflammatory cytokines in the patients with chronic hepatitis C.
Mihăilă R; Nedelcu L; Frăţilă O; Rezi EC; Domnariu C; Ciucă R; Zaharie AV; Olteanu A; Bera L; Deac M; Mihăilă R
Hepatogastroenterology; 2009; 56(96):1704-9. PubMed ID: 20214221
[TBL] [Abstract][Full Text] [Related]
19. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
[TBL] [Abstract][Full Text] [Related]
20. Fluvastatin improves lipid abnormalities in patients with moderate to advanced chronic renal insufficiency.
Samuelsson O; Attman PO; Knight-Gibson C; Mulec H; Weiss L; Alaupovic P
Am J Kidney Dis; 2002 Jan; 39(1):67-75. PubMed ID: 11774104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
